Hematology Frontier

In January 2023, a review by Professor Tao Cheng  from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published in the international academic journal ——Blood Science . The title of the study is "Spatially resolved transcriptomics: advances and applications". This review summarizes the interplay between technological innovation and biological discovery continues to push the boundaries of what was previously imaginable, translating our approach to complex biological systems and disease pathology.

Recently, the Blood Transfusion Department at The First Hospital of Handan in Hebei Province identified an extremely rare B subtype blood type. This blood type results from a heterozygous mutation in exon 7 of the ABO allele, specifically c.449A>G, making it even rarer than the well-known "Panda Blood" (Rh-negative blood).

In the evolving field of hematology and oncology, addressing acute myeloid leukemia (AML) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is crucial. A recent study highlighting AML relapse as pericardial effusion marks significant progress in this area. Led by Professor Sizhou Feng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, this research underscores innovative diagnostic and therapeutic strategies.

In the dynamic field of hematology and oncology, finding effective treatments for Waldenstrom macroglobulinemia (WM) is crucial. A recent study led by Professor Shuhua Yi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,  has made significant strides in this area. This research analyzed first- and second-line therapies in 377 patients with WM, demonstrating that sequential treatment escalation markedly improves survival rates. By transitioning from cytotoxic drugs to rituximab, bortezomib, or Bruton tyrosine kinase inhibitors, patients saw significant benefits. These findings, presented at a major medical conference, underscore the collaborative effort and innovation driving progress in hematology and improving patient outcomes.

In the dynamic field of hematology and oncology, the development of innovative treatments for challenging conditions such as relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) remains a critical priority. In this commentary, the recent phase 2 clinical trial investigating the efficacy of sequential CD19 and CD22 CAR T-cell therapies represents a significant advancement in the therapeutic landscape. Professor Kailin Xu from the Affiliated Hospital of Xuzhou Medical University, along with esteemed colleagues, offers new hope for patients facing this aggressive malignancy. He highlighted the findings of this pioneering research, published in the Lancet Oncology, which reported not only the potential of sequential CD19 and CD22 CAR T-cell therapy as a viable treatment option, but also the collaborative effort and expertise that exemplify the spirit of innovation in the field.

Despite significant improvements in the survival of multiple myeloma (MM) patients over the past two decades, thanks to the emergence of new drugs and therapies, the prognosis for those not eligible for bone marrow transplantation remains relatively poor. Therefore, there is an urgent need to explore new treatment options to improve their outcomes. At the recently held 29th Annual Congress of the European Hematology Association (EHA 2024), Professor Thierry Facon, a member of the International Myeloma Working Group (IMWG) and from the University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France, presented the key findings of the IMROZ study in an oral report. This study explored the efficacy of isatuximab combined with the VRD regimen (Isa-VRD) in treating newly diagnosed MM patients not suitable for transplantation, and the results were published in the New England Journal of Medicine (NEJM) in early June this year. "Oncology Frontier-Hematology Frontier" specially invited Professor Thierry Facon to share the important findings and significance of the IMROZ study at the venue.

Acute promyelocytic leukemia (APL) is a highly aggressive hematological disease, and its treatment has long been a challenge in the field. Chinese scholars have contributed significantly to global APL treatment with the introduction of the arsenic trioxide (ATO) regimen. Since the publication of the APL0406 study in NEJM in 2013, the combination of all-trans retinoic acid (ATRA) and ATO has replaced ATRA combined with chemotherapy as the standard treatment for low- and intermediate-risk APL patients. However, whether this regimen is suitable for high-risk APL patients remains undetermined due to a lack of randomized controlled trials. At the 29th Annual Meeting of the European Hematology Association (EHA 2024) held from June 13-16, 2024, Dr. Uwe Platzbecker from the Leipzig University in Germany presented key findings from the APOLLO study. This study demonstrated that the combination of ATO and ATRA offers a new treatment strategy for high-risk APL patients, providing valuable insights into the current state of APL treatment and guiding future research directions and clinical practices. Oncology Frontier - Hematology Frontier invited Professor Platzbecker to share the important discoveries and clinical significance of the APOLLO study.

With the rapid development in the field of hematology, new treatment strategies and breakthrough advancements continue to emerge, offering new hope for patients with hematological malignancies. At the 2024 EHA conference, "Oncology Frontier-Hematology Frontier" had the honor of interviewing Professor Meletios A. Dimopoulos from the School of Medicine, National and Kapodistrian University of Athens School of Medicine, delving into the challenges currently faced in the treatment of hematological malignancies, especially for those patients who are refractory to traditional treatments such as lenalidomide and anti-CD38 monoclonal antibody therapy. Professor Dimopoulos' phase 3 DREAMM-8 study data demonstrated the potential and advantages of the B-Pd combination treatment regimen, providing a new option for second-line treatment.